uniQure N.V.

NasdaqGS QURE

uniQure N.V. EBITDA for the year ending December 31, 2023: USD -253.10 M

uniQure N.V. EBITDA is USD -253.10 M for the year ending December 31, 2023, a -134.31% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

uniQure N.V. EBITDA for the year ending December 31, 2022 was USD -108.02 M, a -133.86% change year over year.
uniQure N.V. EBITDA for the year ending December 31, 2021 was USD 319.00 M, a 351.24% change year over year.
uniQure N.V. EBITDA for the year ending December 31, 2020 was USD -126.97 M, a -11.58% change year over year.
uniQure N.V. EBITDA for the year ending December 31, 2019 was USD -113.79 M, a -53.74% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: QURE

uniQure N.V.

CEO	Mr. Matthew Craig Kapusta CPA
IPO Date	Feb. 5, 2014
Location	Netherlands
Headquarters	Paasheuvelweg 25a
Employees	480
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key trends

Past 5 years